Use of topical immunomodulators in organ transplant recipients

Dermatologic Therapy

Volumn 18, Issue 1, 2005, Pages 19-27

  Kovach, Bradley T ^a   Stasko, Thomas ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Imiquimod; Immunotherapy; Organ transplantation; Skin neoplasms; Warts

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; CELECOXIB; DICLOFENAC; DIPHENCYPRONE; IMIDAZOQUINOLONE; IMIQUIMOD; IMMUNOMODULATING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; RETINOID; SQUARIC ACID DIBUTYL ESTER; TRIAZIQUONE; UNCLASSIFIED DRUG;

APOPTOSIS; BASAL CELL CARCINOMA; BOWEN DISEASE; CONDYLOMA ACUMINATUM; CONTACT SENSITIZATION; DRUG EFFICACY; EROSION; ERYTHEMA; HUMAN; IMMUNE RESPONSE; MORBIDITY; ORGAN TRANSPLANTATION; PAIN; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SURGICAL MORTALITY; VERRUCA VULGARIS;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; HUMANS; IMMUNOLOGIC FACTORS; ORGAN TRANSPLANTATION; SKIN NEOPLASMS;

EID: 18844405664     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2005.05008.x     Document Type: Review

References (68)

1. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003: 348 (17): 1681-1691.
2. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002: 146 (Suppl. 61): 1-6.
3. Ramsay HM, Fryer AA, Hawley CM et al. Nonmelanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002: 147: 950-956.
4. Jensen P, Hansen S, Møller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999: 40 (1): 177-186.
5. Euvrard S, Kanitakis J, Pouteil-Noble C et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995: 33 (2 Part 1): 222-229.
6. Martinez JC, Otley CC, Stasko T et al. Transplant-Skin Cancer Collaborative. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003: 139 (3): 301-306.
7. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001: 27 (4): 409-413.
8. Penn I. Post-transplant malignancies in pediatric organ transplant recipients. Transplant Proc 1994: 26 (5): 2763-2765.
9. Sheil AG, Disney AP, Mathew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993: 25 (1 Part 2): 1383-1384.
10. Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am 1993: 7 (2): 431-445.
11. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999: 40 (1): 27-34.
12. Stasko T, Brown MD, Carucci JA et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004: 30 (4): 642-650.
13. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001: 137 (4): 459-463.
14. Bavinck JN, Hardie DR, Green A et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996: 61 (5): 715-721.
15. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990: 49 (3): 506-509.
16. Stockfleth E, Nindl I, Sterry W, Ulrich C, Schmook T, Meyer T. Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg 2004: 30 (4 Part 2): 604-609.
17. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000: 43 (1 Part 2): S6-S11.
18. Ito T, Amakawa R, Kaisho T et al. Interferon-alpha and interleukin-12 are induced differentially by toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002: 195 (11): 1507-1512.
19. Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators - progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001: 1 (3): 189-198.
20. Testerman TL, Gerster JF, Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995: 58 (3): 365-372.
21. Hengge UR, Schaller J. Successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol 2004: 140 (4): 404-406.
22. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003: 139 (10): 1325-1332.
23. Burns RP Jr, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod, and R-848, induce functional but not phenotypic maturation of human epidermal Langerhans' cells. Clin Immunol 2000: 94 (1): 13-23.
24. Suzuki H, Wang B, Shivji GM et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000: 114 (1): 135-141.
25. Berman B, Sullivan T, De Araujo T, Nadji M. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003: 149 (Suppl. 66): 59-61.
26. Hesling C, D'Incan M, Mansard S et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 2004: 150 (4): 761-767.
27. Sidbury R, Neuschler N, Neuschler E et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003: 121 (5): 1205-1209.
28. Wang C, Quevedo ME, Lannutti BJ et al. In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. J Invest Dermatol 1999: 112 (5): 775-781.
29. Huber A, Huber JD, Skinner RB Jr, Kuwahara RT, Haque R, Amonette RA. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 2004: 30 (3): 429-430.
30. Eklind J, Tartler U, Maschke J, Lidbrink P, Hengge UR. Imiquimod to treat different cancers of the epidermis. Dermatol Surg 2003: 29 (8): 890-896.
31. Wu JK, Siller G, Whitehead K. Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australas J Dermatol 2003: 44 (2): 123-125.
32. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004: 29 (1): 15-21.
33. Borucki U, Metze D. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology 2003: 207 (3): 326-328.
34. Bhatia N. Imiquimod as a possible treatment for kerato-acanthoma. J Drugs Dermatol 2004: 3 (1): 71-74.
35. + T cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 2004: 150 (6): 1198-1201.
36. Dummer R, Urosevic M, Kempf W, Kazakov D, Burg G. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology 2003: 207 (1): 116-118.
37. Zampogna JC, Flowers FP, Roth WI, Hassenein AM. Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 2003: 47: S229-S235.
38. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003: 139: 273-276.
39. Hengge UR, Goos M, Arndt R. Topical treatment of warts and mollusca with imiquimod. Ann Intern Med 2000: 132 (1): 95.
40. Vidal D, Alomar A. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients. Clin Exp Dermatol 2004: 29 (3): 237-239.
41. Prinz BM, Hafner J, Dummer R, Burg G, Bruswanger U, Kempf W. Treatment of Bowen's disease with imiquimod 5% cream in transplant recipients. Transplantation 2004: 77 (5): 790-791.
42. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001: 27 (6): 561-564.
43. Weisshaar E, Gollnick H. Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients. Acta Derm Venereol 2000: 80 (4): 306-307.
44. Gayed SL. Topical imiquimod cream 5% for resistant perianal warts in a renal transplant patient. Int J STD AIDS 2002: 13 (7): 501-503.
45. Schmook T, Nindl I, Ulrich C, Meyer T, Sterry W, Stockfleth E. Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol 2003: 149 (Suppl. 66): 20-24.
46. Cutler K, Kagen MH, Don PC, McAleer P, Weinberg JM. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus. Acta Derm Venereol 2000: 80 (2): 134-135.
47. Stravitz RT, Shiffman ML, Sanyal AJ et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004: 10 (7): 850-858.
48. Baid S, Tolkoff-Rubin N, Saidman S et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003: 3 (1): 74-78.
49. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Treatment of chronic hepatitis B and C with alpha interferon in a renal transplant patient. Scand J Urol Nephrol 1996: 30 (6): 485-487.
50. Benson E. Imiquimod: potential risk of an immunostimulant. Australas J Dermatol 2004: 45 (2): 123-124.
51. Harrison LI, Skinner SL, Marbury TC et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004: 296 (1): 6-11.
52. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004: 50 (5): 722-733.
53. Ulrich C, Schmook T, Nindl I, Meyer T, Sterry W, Stockfleth E. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol 2003: 149 (Suppl. 66): 40-42.
54. Gibson GE, O'Grady A, Kay EW, Leader M, Murphy GM. Langerhans cells in benign, premalignant and malignant skin lesions of renal transplant recipients and the effect of retinoid therapy. JEADV 1998: 10 (2): 130-136.
55. Servitje O, Seron D, Ferrer I, Carrera M, Pagerols X, Peyri J. Quantitative and morphometric analysis of Langerhans cells in nonexposed skin in renal transplant patients. J Cutan Pathol 1991: 18 (2): 106-111.
56. Thiers BH, Maize JC, Spicer SS, Cantor AB. The effect of aging and chronic sun exposure on human Langerhans cell populations. J Invest Dermatol 1984: 82 (3): 223-226.
57. Viac J, Chardonnet Y, Euvrard S, Chignol MC, Thivolet J. Langerhans cells, inflammation markers and human papillomavirus infections in benign and malignant epithelial tumors from transplant recipients. J Dermatol 1992: 19 (2): 67-77.
58. Rook AH, Jaworsky C, Nguyen T et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995: 59 (5): 714-719.
59. Bachelor MA, Bowden GT. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin Cancer Biol 2004: 14 (2): 131-138.
60. Tripp CS, Blomme EA, Chinn KS, Hardy MM, LaCelle P, Pentland AP. Epidermal COX-2 induction following ultraviolet irradiation: suggested mechanism for the role of COX-2 inhibition in photoprotection. J Invest Dermatol 2003: 121 (4): 853-861.
61. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000: 86 (5): 667-671.
62. Buckman SY, Gresham A, Hale P et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998: 19 (5): 723-729.
63. Herrmann G, Groth W, Krieg T, Mauch C. Complete remission of Merkel cell carcinoma of the scalp with local and regional metastases after topical treatment with dinitrochlorbenzol. J Am Acad Dermatol 2004: 50 (6): 965-969.
64. Lee AN, Mallory SB. Contact immunotherapy with squaric acid dibutylester for the treatment of recalcitrant warts. J Am Acad Dermatol 1999: 41: 595-599.
65. Strobbe LJ, Hart AA, Rumke P et al. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. Melanoma Res 1997: 7: 507-512.
66. Buckley DA, Keane FM, Munn SE et al. Recalcitrant viral warts treated by diphencyprone immunotherapy. Br J Dermatol 1991: 141: 292-296.
67. Dunagin WG, Millikan LE. Dinitrochlorobenzene immunotherapy for verrucae resistant to standard treatment modalities. J Am Acad Dermatol 1982: 6: 40-45.
68. Clayton AS, Stasko T. Treatment of nonmelanoma skin cancer in organ transplant recipients: review of responses to a survey. J Am Acad Dermatol 2003: 49 (3): 413-416.